PE20221462A1 - Composiciones y metodos para la activacion de integrinas - Google Patents
Composiciones y metodos para la activacion de integrinasInfo
- Publication number
- PE20221462A1 PE20221462A1 PE2022000784A PE2022000784A PE20221462A1 PE 20221462 A1 PE20221462 A1 PE 20221462A1 PE 2022000784 A PE2022000784 A PE 2022000784A PE 2022000784 A PE2022000784 A PE 2022000784A PE 20221462 A1 PE20221462 A1 PE 20221462A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- alpha6
- alpha7
- alpha3
- integrin
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 9
- 102000004169 proteins and genes Human genes 0.000 abstract 9
- 108010072255 Integrin alpha3beta1 Proteins 0.000 abstract 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 abstract 1
- 102000007547 Laminin Human genes 0.000 abstract 1
- 108010085895 Laminin Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invencion proporciona un agente farmaceutico que es un agonista de al menos una de la integrina alfa7beta1, integrina alfa6beta1 e integrina alfa3beta1 y que se une a al menos uno de: el dominio de union a laminina de al menos una de la proteina alfa7, proteina alfa6 y proteina alfa3; el dominio CALF-1 de al menos una de la proteina alfa7, proteina alfa6 y proteina alfa3; y el dominio CALF-2 de al menos una de la proteina alfa7, proteina alfa6 y proteina alfa3. Dicho agente es un anticuerpo monoclonal, multiespecifico o biespecifico. Tambien proporcionan una composicion farmaceutica que lo comprende; siendo utiles para tratar enfermedades relacionadas con el mal funcionamiento muscular, que incluyen distrofias musculares.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935732P | 2019-11-15 | 2019-11-15 | |
| US202063009020P | 2020-04-13 | 2020-04-13 | |
| US202063029070P | 2020-05-22 | 2020-05-22 | |
| PCT/US2020/060574 WO2021097338A1 (en) | 2019-11-15 | 2020-11-13 | Compositions and methods for activation of integrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221462A1 true PE20221462A1 (es) | 2022-09-21 |
Family
ID=73740612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000784A PE20221462A1 (es) | 2019-11-15 | 2020-11-13 | Composiciones y metodos para la activacion de integrinas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12134642B2 (es) |
| EP (1) | EP4058481A1 (es) |
| JP (1) | JP2023503851A (es) |
| KR (1) | KR20220113386A (es) |
| CN (1) | CN115151566A (es) |
| AU (1) | AU2020381534A1 (es) |
| BR (1) | BR112022009430A2 (es) |
| CA (1) | CA3163339A1 (es) |
| CL (1) | CL2022001261A1 (es) |
| CO (1) | CO2022006653A2 (es) |
| EC (1) | ECSP22043116A (es) |
| IL (1) | IL292773A (es) |
| MX (1) | MX2022005904A (es) |
| PE (1) | PE20221462A1 (es) |
| PH (1) | PH12022551166A1 (es) |
| TW (1) | TW202128764A (es) |
| WO (1) | WO2021097338A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| JP7579805B2 (ja) | 2019-04-08 | 2024-11-08 | プライアント・セラピューティクス・インコーポレイテッド | アミノ酸化合物の剤形およびレジメン |
| CN115151566A (zh) | 2019-11-15 | 2022-10-04 | 普利安特治疗公司 | 用于活化整合素的组合物和方法 |
| PE20240114A1 (es) | 2020-11-19 | 2024-01-22 | Pliant Therapeutics Inc | Inhibidor de integrina y usos de este |
| WO2025194093A2 (en) * | 2024-03-15 | 2025-09-18 | Morphic Therapeutic, Inc. | INTEGRIN α7β1 ANTIBODIES AND USES THEREOF |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61122292A (ja) | 1984-11-16 | 1986-06-10 | Teijin Ltd | 新規カルバサイクリン中間体の製法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69531187T2 (de) | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
| WO2002066989A2 (en) | 2001-02-20 | 2002-08-29 | The Board Of Trustees Of The University Of Illinois | Diagnostics, assay methods and amelioration of muscular dystrophy symptoms |
| CN115151566A (zh) | 2019-11-15 | 2022-10-04 | 普利安特治疗公司 | 用于活化整合素的组合物和方法 |
-
2020
- 2020-11-13 CN CN202080092561.2A patent/CN115151566A/zh active Pending
- 2020-11-13 WO PCT/US2020/060574 patent/WO2021097338A1/en not_active Ceased
- 2020-11-13 BR BR112022009430A patent/BR112022009430A2/pt unknown
- 2020-11-13 KR KR1020227019365A patent/KR20220113386A/ko active Pending
- 2020-11-13 EP EP20820723.3A patent/EP4058481A1/en active Pending
- 2020-11-13 MX MX2022005904A patent/MX2022005904A/es unknown
- 2020-11-13 PH PH1/2022/551166A patent/PH12022551166A1/en unknown
- 2020-11-13 JP JP2022527988A patent/JP2023503851A/ja active Pending
- 2020-11-13 CA CA3163339A patent/CA3163339A1/en active Pending
- 2020-11-13 US US17/098,199 patent/US12134642B2/en active Active
- 2020-11-13 AU AU2020381534A patent/AU2020381534A1/en active Pending
- 2020-11-13 PE PE2022000784A patent/PE20221462A1/es unknown
- 2020-11-16 TW TW109139995A patent/TW202128764A/zh unknown
-
2022
- 2022-05-04 IL IL292773A patent/IL292773A/en unknown
- 2022-05-13 CL CL2022001261A patent/CL2022001261A1/es unknown
- 2022-05-19 CO CONC2022/0006653A patent/CO2022006653A2/es unknown
- 2022-05-30 EC ECSENADI202243116A patent/ECSP22043116A/es unknown
-
2024
- 2024-09-30 US US18/902,760 patent/US20250026819A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL292773A (en) | 2022-07-01 |
| CN115151566A (zh) | 2022-10-04 |
| BR112022009430A2 (pt) | 2022-10-25 |
| CA3163339A1 (en) | 2021-05-20 |
| CL2022001261A1 (es) | 2023-03-17 |
| KR20220113386A (ko) | 2022-08-12 |
| WO2021097338A1 (en) | 2021-05-20 |
| JP2023503851A (ja) | 2023-02-01 |
| PH12022551166A1 (en) | 2023-10-02 |
| AU2020381534A1 (en) | 2022-06-23 |
| MX2022005904A (es) | 2022-09-07 |
| CO2022006653A2 (es) | 2022-08-09 |
| ECSP22043116A (es) | 2022-08-31 |
| TW202128764A (zh) | 2021-08-01 |
| US20250026819A1 (en) | 2025-01-23 |
| US12134642B2 (en) | 2024-11-05 |
| US20210147526A1 (en) | 2021-05-20 |
| EP4058481A1 (en) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221462A1 (es) | Composiciones y metodos para la activacion de integrinas | |
| CL2021002657A1 (es) | Un anticuerpo antagonista que se une específicamente a vista humano, una composición farmacéutica que lo comprende; y eso uso de los mismos para el tratamiento del cáncer o una enfermedad infecciosa (divisional de la solicitud 201802925) | |
| EA201891694A1 (ru) | Фармацевтическая композиция, содержащая конструкты биспецифических антител | |
| CL2016002585A1 (es) | Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373) | |
| AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| PE20210652A1 (es) | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl | |
| CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
| CL2017001866A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| GT200900002A (es) | Anticuerpo antagonista para el tratamiento del cancer | |
| BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| MX386942B (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| CL2024002319A1 (es) | Anticuerpo de cadena pesada que se unen a cd22; composición farmacéutica; y su uso. | |
| PE20100251A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
| BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
| EA201991769A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК | |
| AR069775A1 (es) | Anticuerpos bivalentes biespecificos | |
| EA201201533A1 (ru) | Prlr-специфическое антитело и его применения | |
| EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения |